HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast

[1]  G. Viale,et al.  Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status , 2022, Virchows Archiv.

[2]  Yan Song,et al.  Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer , 2022, Laboratory Investigation.

[3]  A. Nicholson,et al.  Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. , 2022, Cancer treatment reviews.

[4]  L. Pusztai,et al.  Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. , 2022, JAMA oncology.

[5]  A. Wolff,et al.  ERBB2-Low Breast Cancer-Is It a Fact or Fiction, and Do We Have the Right Assay? , 2022, JAMA oncology.

[6]  S. Loi,et al.  ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Fassan,et al.  Evolution of HER2-low expression from primary to recurrent breast cancer , 2021, NPJ breast cancer.

[8]  A. Lluch,et al.  Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer , 2021, NPJ breast cancer.

[9]  S. Y. Park,et al.  HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation , 2019, Journal of pathology and translational medicine.

[10]  T. Agatsuma,et al.  The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. , 2019, Chemical & pharmaceutical bulletin.

[11]  S. Shuangshoti,et al.  Comparison between digital image analysis and visual assessment of immunohistochemical HER2 expression in breast cancer. , 2018, Pathology, research and practice.

[12]  Michel E. Vandenberghe,et al.  Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer , 2017, Scientific Reports.

[13]  Sridhar Ramaswamy,et al.  HER2 expression identifies dynamic functional states within circulating breast cancer cells , 2016, Nature.

[14]  T. Agatsuma,et al.  Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity , 2016, Cancer science.

[15]  John W. Adams,et al.  Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival , 2015, Breast Cancer Research.

[16]  J Bogaerts,et al.  High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  P. Moore,et al.  Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties , 2011, Breast Cancer Research.

[18]  E. Mallon,et al.  IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest™ in breast carcinoma , 2005, Journal of Clinical Pathology.